AlphAIAlphAI — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · BIOTECHNOLOGY

$LONA

LeonaBio, Inc.

Price · $LONAvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $LONA in the last 7 days.

Insider · 30dAll trades →

No SEC Form 4 filings for $LONA in the last 30 days.

See all $LONA insider activity →
Top stories · $LONAMore →
AUG 28·theglobeandmail.comLow

Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB)

Analysts from Piper Sandler and Cantor Fitzgerald maintained Buy ratings on NeoGenomics (NEO), LeonaBio (LONA), and Solid Biosciences (SLDB). NeoGenomics has a $21.00 target, LeonaBio a $20.00 target, and Solid Biosciences a $26.00 target. Consensus ratings are Moderate Buy for NEO and Strong Buy for LONA and SLDB, with respective average targets of $18.33, $17.33, and $19.17.

AUG 17·yahoo.com

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

LeonaBio (NASDAQ:LONA) reported a Q2 loss of $0.80 per share, smaller than analysts’ $1.12 forecast. Net loss rose to $19.0 million from $7.0 million a year earlier. Phase 3 ELAINE-3 enrollment nears 600 target, with 495 patients enrolled and topline results expected in H2 2027. Cash fell to $51.1 million from $88.3 million.

AUG 14·SEC EDGAR 8-K

LeonaBio, Inc. (LONA): Results of Operations and Financial Condition

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline D

LONA sentiment & insider activity

Recent LONA coverage spans earnings, financial news and corporate actions.

What's driving LONA

  • Analyst maintains bullish stance with a significant upside target.

    theglobeandmail.com · Aug 28, 2026

  • The beat reduces near-term downside risk, but the bigger driver is continued execution toward ELAINE-3 recruitment completion in Q4 2026 and topline in H2 2027.

    yahoo.com · Aug 17, 2026

  • Near-term trading focus is ELAINE-3 enrollment progress and the company’s funding runway via cash-exercisable warrants, with additional pipeline updates.

    SEC EDGAR 8-K · Aug 14, 2026

  • This is routine corporate governance disclosure (annual meeting outcomes) with no new operating, financial, or legal catalyst.

    SEC EDGAR 8-K · Jun 23, 2026

AlphAI scores every news story that mentions LONA with an AI model for sentiment and relevance, and aggregates insider trades from LeonaBio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $LONA

Score
AUG 28$NEOLowtheglobeandmail.com

Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB)

Analysts from Piper Sandler and Cantor Fitzgerald maintained Buy ratings on NeoGenomics (NEO), LeonaBio (LONA), and Solid Biosciences (SLDB). NeoGenomics has a $21.00 target, LeonaBio a $20.00 target, and Solid Biosciences a $26.00 target. Consensus ratings are Moderate Buy for NEO and Strong Buy for LONA and SLDB, with respective average targets of $18.33, $17.33, and $19.17.

2 min read
AUG 17$LONAMedyahoo.com

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

LeonaBio (NASDAQ:LONA) reported a Q2 loss of $0.80 per share, smaller than analysts’ $1.12 forecast. Net loss rose to $19.0 million from $7.0 million a year earlier. Phase 3 ELAINE-3 enrollment nears 600 target, with 495 patients enrolled and topline results expected in H2 2027. Cash fell to $51.1 million from $88.3 million.

4 min read
AUG 14$LONAMedSEC EDGAR 8-K

LeonaBio, Inc. (LONA): Results of Operations and Financial Condition

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline D

6 min read
JUN 23$LONALowSEC EDGAR 8-K

LeonaBio, Inc. (LONA): Submission of Matters to a Vote of Security Holders

LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001620463 0001620463 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,

1 min read

Related tickers

More in BIOTECHNOLOGY